What question did this study set out to answer?

February 12, 2026Open Access

Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study

Key Points

To evaluate the real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease.
Conducted a single-center retrospective study
Included patients with moderate-to-severe inflammatory bowel disease
Assessed effectiveness and safety over a 6-month period
Upadacitinib was effective in reducing symptoms of inflammatory bowel disease
Well tolerated among patients, including those previously treated with biologics
Findings support its routine clinical use but emphasize the need for further studies in Asian populations

Abstract

Upadacitinib was effective and well tolerated over 6 months in Korean patients with moderate-to-severe IBD, including those with biologic-experienced patients. These findings support its use in routine clinical practice, while highlighting the need for prospective studies to confirm its long-term safety and efficacy in Asian populations.

Bookmark

View Full Paper

Cite This Study

Kim et al. (Tue,) studied this question.

synapsesocial.com/papers/698d6d9f5be6419ac0d52aed https://doi.org/https://doi.org/10.5217/ir.2025.00235

Bookmark

View Full Paper